Literature DB >> 31746301

miR-4319 Suppresses the Growth of Esophageal Squamous Cell Carcinoma Via Targeting NLRC5.

Xiao Hu1, Min Wang2, Lei Cao1, Li Cong1, Yujie Gao1, Jianwei Lu3, Jifeng Feng3, Bo Shen3, Delin Liu3.   

Abstract

BACKGROUND: The functions of microRNAs (miRNAs) in cancer progression have been recognized in recent years. However, the role of miR-4319 in esophageal squamous cell carcinoma (ESCC) remains unclear.
OBJECTIVE: We aimed to investigate the biological roles of miR-4319 in ESCC progression and the associated mechanisms.
METHODS: Real-time PCR was performed to examine the levels of miR-4319 in ESCC cell lines. The effects of miR-4319 and NOD-like receptor (NLR) family, caspase activation and recruitment domain (CARD) domain containing 5 (NLRC5) on cell proliferation and cell cycle progression were evaluated using MTT assay, colony formation and flow cytometry assays. Bioinformatics techniques and luciferase reporter assay were applied to validate NLRC5 as a miR-4319 target.
RESULTS: The miR-4319 expression was lower in ESCC cells than in the normal cell line. The expression of miR-4319 repressed cell growth and induced cell cycle arrest. NLRC5 was validated as a direct downstream target of miR-4319. Overexpression of NLRC5 potentiated the effects of miR-4319 on cell growth and cell cycle distribution.
CONCLUSION: Our results demonstrated that miR-4319 might function as a tumor suppressor by targeting NLRC5 in ESCC. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  NLRC5; cell culture; cell cycle; cell growth; esophageal squamous cell carcinoma; miR-4319.

Mesh:

Substances:

Year:  2020        PMID: 31746301     DOI: 10.2174/1874467212666191119094636

Source DB:  PubMed          Journal:  Curr Mol Pharmacol        ISSN: 1874-4672            Impact factor:   3.339


  8 in total

1.  LncRNA ZNF883-Mediated NLRP3 Inflammasome Activation and Epilepsy Development Involve USP47 Upregulation.

Authors:  Lina Gong; Yaru Han; Ru Chen; Pu Yang; Chen Zhang
Journal:  Mol Neurobiol       Date:  2022-06-09       Impact factor: 5.682

2.  LncRNA PCAT18 Promotes Non-Small Cell Lung Cancer Progression by Sponging miR-4319.

Authors:  Li He; Jianjun Wang; Long Zhou; Xiaobing Li
Journal:  Cancer Manag Res       Date:  2021-05-10       Impact factor: 3.989

Review 3.  The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy.

Authors:  Akhil Shukla; Maryse Cloutier; Madanraj Appiya Santharam; Sheela Ramanathan; Subburaj Ilangumaran
Journal:  Int J Mol Sci       Date:  2021-02-17       Impact factor: 5.923

4.  LIN28A inhibits DUSP family phosphatases and activates MAPK signaling pathway to maintain pluripotency in porcine induced pluripotent stem cells.

Authors:  Xiao-Long Wu; Zhen-Shuo Zhu; Xia Xiao; Zhe Zhou; Shuai Yu; Qiao-Yan Shen; Ju-Qing Zhang; Wei Yue; Rui Zhang; Xin He; Sha Peng; Shi-Qiang Zhang; Na Li; Ming-Zhi Liao; Jin-Lian Hua
Journal:  Zool Res       Date:  2021-05-18

5.  NLRC5 Might Promote Endometrial Cancer Progression by Inducing PD-L1 Expression.

Authors:  Su-Ding Zhu; Jing Zhang; Xiao-Jing Liu; Jun-Hui Zhang; Bing Wei; Wen-Yan Wang; Yi-Jun Fan; Dan Li; Yun-Xia Cao; Lei Zhan
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 6.  MicroRNAs, Tristetraprolin Family Members and HuR: A Complex Interplay Controlling Cancer-Related Processes.

Authors:  Cyril Sobolewski; Laurent Dubuquoy; Noémie Legrand
Journal:  Cancers (Basel)       Date:  2022-07-20       Impact factor: 6.575

7.  Long intergenic non‑coding RNA LINC01232 contributes to esophageal squamous cell carcinoma progression by sequestering microRNA‑654‑3p and consequently promoting hepatoma‑derived growth factor expression.

Authors:  Meihua Zhao; Haishan Cui; Baisui Zhao; Mei Li; Haiqing Man
Journal:  Int J Mol Med       Date:  2020-10-09       Impact factor: 4.101

8.  KCNQ1OT1 accelerates gastric cancer progression via miR-4319/DRAM2 axis.

Authors:  Jijun Wang; Fan Wu; Yaoyao Li; Lei Pang; Xiaohong Wang; Guimei Kong; Tong Zhang; Duonan Yu
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.